MedTrace Logo

Coronary Artery Disease (CAD) in Suppressed HIV-infected

NCT02898896 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2019-08-12

No results posted yet for this study

Summary

HIV-infected patients with intermediate-high risk have a high prevalence of CAD and a substantial proportion of obstructive CAD. Degree of stenosis is associated with immunoactivation (lymphocyte and monocyte) and microbial translocation

Conditions

  • Virus-HIV

Interventions

BIOLOGICAL

blood test

Additional 21 ml of blood will be collected

Sponsors & Collaborators

  • Hospital Universitario La Paz

    collaborator OTHER

  • Hospital Reina Sofia, Murcia

    collaborator UNKNOWN

  • Hospital Vall D' Hebron Barcelon

    collaborator UNKNOWN

  • Patras University Hospital, Patras

    collaborator UNKNOWN

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Christina PSOMAS · University Hospital, Montpellier

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
48 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2018-01-05
Completion
2018-01-05

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02898896 on ClinicalTrials.gov